No Data
No Data
Harbin Gloria Pharmaceuticals (002437.SZ): No plans to repurchase company shares.
Gelonghui, December 2nd | Harbin Gloria Pharmaceuticals (002437.SZ) announced that as of November 30, 2024, the company has not yet repurchased its shares through the dedicated securities repurchase account.
Harbin Gloria Pharmaceuticals (002437.SZ): Director Wang Dongxu has completed a shareholding reduction of 0.21 million shares.
On December 2, Gelonhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) announced that on December 2, 2024, the company received a notification letter on the progress of the shareholding plan issued by Director Mr. Wang Dongxu. Mr. Wang Dongxu's shareholding plan has been fully implemented; he has cumulatively reduced holdings by 0.21 million shares, a reduction rate of 0.0092%.
Do Its Financials Have Any Role To Play In Driving HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Stock Up Recently?
Harbin Gloria Pharmaceuticals (002437.SZ): Received special financing support for repurchasing company shares.
Gloria Pharmaceuticals (002437.SZ) announced on October 31 that it has received a "Loan Commitment Letter" from Bank of China Harbin Pingfang Branch, committing to provide the company with a maximum of 70 million RMB of loan funds specifically for share buyback. The obtaining of the aforementioned loan commitment letter can provide financing support for the company's share buyback. The specific loan matters will be subject to the loan contract signed by both parties, and the company will actively implement the share buyback according to the share buyback plan.
Yuheng Pharmaceutical: Report for the third quarter of 2024
A Look At The Intrinsic Value Of HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437)